In Reply We appreciate the opportunity to respond to the letters from Rasminsky and Burt and Miller et al. Regarding the comments of Rasminsky and Burt, we noted the small effect sizes in our article.1 In our view, this was not surprising given that there are likely many contributory exposures and genetic factors responsible for speech and language disturbances. Moreover, given that serotonin reuptake inhibitors (SSRIs) are taken by millions of women during pregnancy, the public health impact to the population may be substantial. Furthermore, we acknowledged other design limitations and note the importance of replication of our findings in independent cohorts. We were also transparent with our data. Owing to the journal’s understandable restrictions on numbers of tables and the need to make the tables readable, the frequency data on those with speech/language disorders were included in a supplemental table.
Brown AS, Malm H, Sourander A. Serotonin Reuptake Inhibitor Use During Pregnancy—Reply. JAMA Psychiatry. 2017;74(5):539–540. doi:10.1001/jamapsychiatry.2016.4065
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.